The NIH announced on April 28 several clarifications about new due dates, clarification of eligibility, extension of expiration dates and more through the NIH Funding Twitter feed.
If you do not follow NIH Funding through the Twitter feed, you are missing out on first notice on most NIH funding. New funding and changes are usually posted on Twitter within an hour of being placed in the official record. With the new Notice of Special Interest guidelines, joining this feed is a must for researchers seriously interested in expanding their NIH portfolio.
Some of the RFAs receiving clarification on April 28 include:
NOT-AG-20-030 Notice of Change to PAR-18-544 "Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional)"
NOT-AI-20-045 Notice of Clarification to Eligibility Information in RFA- AI-20-029 “Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) (U01 Clinical Trial Optional)”
NOT-AI-20-046 Notice of Change in Key Dates for RFA-AI-20-008 , “Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional)”
NOT-CA-20-056 Notice of Change to Application Due Date for RFA-CA-19-045 "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)"
NOT-CA-20-057 RFA-CA-20-027 and RFA-CA-20-028, "Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01/R21 Clinical Trial Optional)
NOT-DA-20-051 Notice of An Additional Cycle of Receipt Dates Added to RFA-DA-20-028 “Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required)"
NOT-NS-20-055 Notice of Extension of Expiration Date for PAR-18-542 "CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)" For more CREATE Bio Development Track clarifications see: NOT-NS-20-053, NOT-NS-20-054, NOT-NS-20-056
NOT-TR-20-025 Notice to Extend the Expiration Date for PAR-17-465 "Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)"